Outcomes after HIFU and prognosis based on post-HIFU PSA nadir levels

A new analysis of data from the multi-center @-Registry of patients undergoing Ablatherm-based high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer suggests that nadir levels of PSA post-treatment can be used to predict the probability of biochemical progression-free survival (bPFS) at 5 years of follow-up.

HIFU as a salvage treatment option after radical prostatectomy

The standard form of treatment for a man with a rising PSA after a first-line radical prostatectomy (RP) is salvage radiation therapy (with or without a period of androgen deprivation). However, an Italian group has just published pilot data on the use of high-intensity focused ultrasound (HIFU) as salvage therapy after RP.

Focal (hemiablative) HIFU in the treatment of localized prostate cancer

To date there have been few data from well-documented, prospective series of patients receiving any form of focal therapy as treatment for localized prostate cancer, and the criteria for the appropriate clinical use of focal therapy are still a matter of considerable debate.

French government implements special reimbursement policy for HIFU

According to a media release this morning the French national health authority (HAS) has put in place a special temporary reimbursement policy that will cover the use of high intensity focused ultrasound (HIFU) only for selected uses of this technique in the management of prostate cancer.

Salvage surgery as second-line therapy after HIFU for localized prostate cancer

High-intensity focused ultrasound (HIFU) is approved in Canada for the treatment of localized prostate cancer. Since its approval, this form of treatment has become popular among patients seeking a potentially curative form of treatment with low risk for complications and side effects.

5-year outcomes data from a French series of HIFU patients

A new report from a French research team has provided detailed 5-year data on the oncological outcomes of a series of low- and intermediate-risk prostate cancer patients treated with high-intensity ultrasound (HIFU) using second-generation Ablatherem™ equipment.

An unenthusiastic review of HIFU in prostate cancer

The potential value of high-intensity focused ultrasound (HIFU) as a treatment for prostate cancer continues to foment controversy between its advocates and its detractors.

A new review of recent clinical outcomes after HIFU

High-intensity focused ultrasound (HIFU) continues to gain advocates as a minimally invasive form of treatment for patients with localized and locally advanced prostate cancer, as well as for patients requiring salvage therapy after first-line radiation and after radical prostatectomy.

Bladder outlet obstruction: a common side effect of HIFU

The occurrence of bladder outlet obstruction (BOO) as a complication following the use of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer has been widely recognized since the early, investigational use of HIFU in the 1990s.

Canadian practice guideline does NOT recommend HIFU

High-intensity focused ultrasound (HIFU) is legally available in Canada as a method for the treatment of prostate cancer. However, a new Canadian practice guideline states that, “HIFU cannot currently be recommended as an alternative to accepted curative treatment approaches for localized prostate cancer.”

Oncologic outcomes of HIFU for localized prostate cancer in 800+ patients

An article still to be formally published in European Urology provides data on the outcomes of 803 patients with localized prostate cancer, all treated with high-intensity focused ultrasound (HIFU) between 1993 and 2007 at six centers in France.

Post-treatment pathology of the prostate after first-line HIFU

One of the unknown factors in the use of high-intensity focused ultrasound (HIFU) for the first-line treatment of prostate cancer is the potential for high-quality, biochemical recurrence-free survival over time. Post-treatment histopathology may offer some insight into the likelihood of good outcomes.

HIFU as salvage therapy for radiation failure

One of the proposed uses for high-intensity focused ultrasound (HIFU)  has been as a treatment option for men with a rising PSA after first-line treatment with external beam radiation therapy (EBRT).

HIFU is not necessarily as safe as suggested

We want to again make the point that treatment of localized prostate cancer with high-intensity focused ultrasound (HIFU), in the hands of inexperienced clinicians, is not necessarily as safe as some of the sales pitches might suggest. In the hands of highly experienced or highly trained HIFU practioners, with access to second- and third-generation equipment, [...]

What the Belgian health authorities think about HIFU

We have learned that last October the “Federaal Kenniscentrum voor de Gezondheidszorg”  or KCE in Brussels, Belgium (the “Federal Center for Health Care Knowledge”) published a guidance document on the current use of high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer.

Follow

Get every new post delivered to your Inbox.

Join 325 other followers